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A B S T R A C T
Prevention of graft-versus-host disease (GVHD) is paramount for allogeneic hematopoietic stem cell trans-
plantation (HSCT) to treat nonmalignant diseases.We previously reported that allogeneic HSCT for severe aplastic
anemia (SAA) using the ﬂudarabine, cyclophosphamide, and alemtuzumab (Campath-1H) (FCC) regimen is
associated with a very low risk of GVHD and excellent clinical outcomes. We now report a single-center study
of 45 patients with longer follow-up and investigation of lymphocyte recovery. Overall survival (OS) was 93%,
and event-free survival (EFS) was 90.7%. Acute and chronic GVHD each occurred in 6 patients (13.3%), and
only 1 case was severe. Mixed T cell chimerism was frequent and persisted after cessation of immunosup-
pression. T cells were extensively depleted, representing only 11.3% of lymphocytes at day 30 and rising to
43.8% by 1 year, but still signiﬁcantly below normal levels (67.2%; P = .018), and deﬁciency persisted after im-
munosuppressive therapy (IST) withdrawal. Depletion of CD4 T cells was particularly profound, causing inversion
of the normal CD4:CD8 T cell ratio. T cell subset composition was also abnormal, with memory and effector
T cells predominating for at least 6 months after FCC HSCT. Analysis of T cell subset chimerism showed that
CD4 T cells were predominantly donor-derived at 1 year, whereas recipient-derived CD8 T cells shaped mixed
chimerism with a notable contribution of recipient effector CD8 T cells. The prolonged mixed T cell chime-
rism after IST withdrawal and low incidence of GVHD indicates the establishment of mutual tolerance, but
the low incidence of viral disease suggests maintenance of antiviral immunity. Our study shows that despite
the abnormal T cell proﬁle after allogeneic HSCT for SAA using the FCC regimen, this regimen is conducive to
an excellent clinical outcome.
© 2016 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
INTRODUCTION
In contrast to hematologicmalignancies, patients with non-
malignant diseases derive no beneﬁt from graft-versus-host
disease after allogeneic hematopoietic stem cell transplanta-
tion. In vivo T cell depletion (TCD) is used to reduce GVHD.We
pioneered the use of alemtuzumab instead of antithymocyte
globulin (ATG) for allogeneicHSCTwith TCD to treat severe aplas-
tic anemia (SAA). Using the FCC conditioning regimen of
ﬂudarabine, low-dose cyclophosphamide, and alemtuzumab
(Campath-1H), we previously reported in a retrospective mul-
ticenter study an overall survival (OS) of 85% to 90% and a
remarkably low incidence of chronic GVHD [1,2]. Subsequent
studies have conﬁrmed the beneﬁt of alemtuzumab over ATG
in reducing both acute and chronic GVHD inHSCT for SAA [3-5].
A recent large multicenter study examining cyclophospha-
mide dosage deescalation in unrelated donorHSCT for SAAusing
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ATG conﬁrmed excellent OS but reported the 1-year incidence
of chronic GVHD of 22.5% to 31.7%, depending on the cyclo-
phosphamide dose used [6]. AllogeneicHSCTwith alemtuzumab
for TCD also has been applied to the treatment of sickle cell
anemia, with excellent clinical outcomes reported [7].
Previous studies of chimerism post-HSCT for SAA exam-
ining unfractionated blood mononuclear cells have shown a
signiﬁcant incidence of mixed chimerism. Although graft
failure occurred in a high proportion of patients with pro-
gressive mixed chimerism, stable mixed chimerism was
associated with a low risk of chronic GVHD [8]. We have pre-
viously reported that stablemixed T cell chimerism alongwith
full donor myeloid engraftment was frequent and persisted
after cessation of post-HSCT immunosuppressive therapy [1].
This effect also has been reported in a proportion of chil-
dren undergoing HSCT for SAA using the FCC regimen [9]. The
very low incidence of GVHD and sustained mixed T cell chi-
merism suggests that a state of mutual immunologic tolerance
exists after FCC HSCT.
In the present study, we investigated the recovery of lym-
phocyte subsets in patients with SAA who underwent HSCT
at King’s College Hospital using the FCC-conditioning regimen.
We report the lymphocyte proﬁle associated with excellent
clinical outcomes, and the basis for the persistent coexis-
tence of donor and recipient T cells.
PATIENTS AND METHODS
Patients
Between 2007 and 2015, 45 consecutive patients with acquired idio-
pathic SAA underwent HSCT at King’s College Hospital. The diagnosis of
aplastic anemia (AA) [10] and disease severity [11,12] were deﬁned using
standard criteria. Fanconi’s anemia was excluded by diepoxybutane stim-
ulation of cultured peripheral blood chromosomes. Patients with likely
constitutional AA, based on an identiﬁed mutation, family history, and/or
somatic anomalies but no identiﬁed mutation, were excluded. Patient char-
acteristics are summarized in Table 1. National Research Ethics Committee
approval was obtained to collect patient samples for research studies via
the King’s College London Haemato-Oncology Tissue Bank, and informed
written consent was obtained in accordance with the Declaration of Helsinki.
Transplantation conditioning regimen
High-resolution DNA typing for HLA-A, -B, -C, -DRB1, and -DQB1 was
performed for all patients. The FCC conditioning regimen was used for 10/
10 HLA-matched HSCT recipients, as described previously [1]. FCC
conditioning with 2 Gy of total body irradiation was used for 9/10 HLA-
matched HSCT recipients. The median alemtuzumab dose was 70mg (range,
45 to 100 mg). Cyclosporine (CSA) alone was used as post-HSCT immuno-
suppressive therapy. Four patients later required the addition of
mycophenolate mofetil owing to renal impairment that precluded full-
dose CSA. Target trough CSA blood levels were 250 to 350 μg/L. IST was
continued for 9 months post-HSCT, followed by tapering over the next 3
months, provided that hematologic parameters and mixed T cell chime-
rism were stable.
Lymphocyte phenotyping
Twenty-nine patients underwent longitudinal multiparameter ﬂow
cytometry analysis of lymphocyte subset reconstitution. Patients who re-
ceived prednisolone or rituximab were excluded after the initiation of
treatment. Analysis of 11 healthy adult volunteers was performed as well.
Cryopreserved peripheral blood mononuclear cells were thawed and labeled
with ﬂuorochrome-conjugated antibodies to characterize lymphocyte subsets.
Analysis was performed by ﬂow cytometry using a FACSCanto II or LSRFortessa
ﬂow cytometer (BD Biosciences, San Diego, CA). Results were analyzed with
FlowJo software (FlowJo, Ashton, OR). Dead cells were excluded from the
analysis based on their forward-scatter and side-scatter properties, and stain-
ing with the Zombie Fixable viability dye (BioLegend, San Diego, CA).
Monocytes were excluded based on expression of CD14. NK cells were deﬁned
as CD3−/CD19−/CD56+. B cells were deﬁned as CD19+. CD4 T cells were deﬁned
as CD3+/CD4+, and CD8 T cells were deﬁned as CD3+/CD8+ with naïve
(CD45RA+/CD27+/CD62L+), memory (CD45RA−/CD27+), effector (CD45RA−/
CD27−/CD62L−), and terminal effector (CD45RA+/CD27−/CD62L−) subsets.
Chimerism
Chimerismwas assessed in unfractionated peripheral blood, CD3+ T cells,
and CD15+ granulocytes. Full donor chimerism was deﬁned as >95% donor
hematopoietic cells. Lymphocyte subsets were isolated using a FACSAria II cell
sorter (BD Biosciences) (purity >95%). Genomic DNA was extracted using a
QIAamp DNA Micro Kit (Qiagen, Venlo, The Netherlands). The percentage of
donor chimerismwas determined using the PowerPlex 16 HSmultiplex short
tandem repeat system for DNA typing (Promega, Madison, WI). Genetic anal-
ysis was performed using an Applied Biosystems 3130xl Genetic Analyzer
(Thermo Fisher Scientiﬁc, Waltham, MA), and results were interpreted using
ChimeRMarker version 3.0.9 (Carolina Biosystems, Orech, Czech Republic).
Statistical analysis
Univariate comparisons and multivariate analysis were performed using
the Cox proportional hazards regression model with SPPS software (IBM,
Armonk, NY). Comparisons of lymphocyte subset composition in patients
and healthy volunteers weremadewith theMann-WhitneyU test using Prism
version 6.0 (GraphPad Software, La Jolla, CA). All tests were 2-tailed, with
a P value <.05 considered statistically signiﬁcant. All data were censored as
of December 30, 2015.
RESULTS
Clinical outcomes after FCC HSCT
In this single-center study, we have conﬁrmed the excel-
lent clinical outcomes reported previously after HSCT using
FCC conditioning for SAA [1] (Table 2). The median dura-
tion of follow-up after HSCT was 31.4 months (range, 3 to 93
months), with excellent OS and event-free survival (EFS) at
5 years of 93% and 91%, respectively. Of note, there was no
signiﬁcant difference in outcomes for recipients of matched
sibling donor transplants compared with recipients of un-
related donor transplants or for patients aged >50 years
(n = 14) compared with younger patients. Three patients died,
resulting in a TRM of 7% at 1 year. The rate of GVHDwas very
Table 1
Patient Pretransplantation Characteristics
Characteristic Value
Number of patients 45
Age, yr, median (range) 32 (15-63)
Age >50 yr, n (%) 14 (31.1)
Males/females, n 28/17
Etiology of aplasia, n (%)
Idiopathic 41 (91.2)
Posthepatitic (seronegative) 2 (4.4)
Eosinophilic fasciitis 1 (2.2)
Celiac disease 1 (2.2)
Type of donor, n (%)
Matched sibling 12 (26.6)
Unrelated 33 (73.4)
9/10 unrelated 8 of 33 (24.2)
Previous immunosuppressive therapy,
n/N (%)
Matched sibling donor 6/12 (50)
Unrelated donor 27/33 (81.8); P = .055
Time to transplantation, d, median (range)
Matched sibling donor 5.9 (2.7-34.7)
Unrelated donor 8.4 (2.1-178.9); P = .095
HLA alloimmunization, n (%) 11 (24.4)
Stem cell source, n (%)
Bone marrow 7 (15.5)
Peripheral blood stem cells 38 (84.5)
PNH clone, n (%) 21 (46.6)
PNH clone size, % median (range)
Granulocytes 2 (0.02-40)
Monocytes 2.85 (0.01-32)
Red cells Not available
Alemtuzumab dose, mg, median (range) 70 (45-100)
CD34+ stem cell dose, × 106/kg, median
(range)
6.55 (1.97-12.40)
Follow-up after HSCT, mo, median (range) 31.4 (3-93)
HSCT indicates hematopoietic stem cell transplantation; PNH, paroxysmal
nocturnal hemoglobinuria.
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low, and the majority of cases were mild. Reliable and sus-
tained engraftment was observed, with only 1 graft failure
noted, in a patient who received a suboptimal bone marrow
infusion cell dose. Sequential chimerism data were avail-
able for 42 patients (93%), which conﬁrmed the persistent
mixed T cell chimerism reported previously with the FCC con-
ditioning regimen [1] (Figure 1A).
Epstein-Barr virus (EBV) viremia was detected in 20 pa-
tients (47%), but treatment was required in only 2 patients
(5%). One patient developed biopsy-proven EBV post-
transplantation lymphoproliferative disease (PTLD) on day 120,
and the second patient had an excessive EBV viral load on
day 66 but no signs of PTLD. Cytomegalovirus (CMV) viremia
was seen in 11 patients (42%), but no patient progressed to
CMV disease, owing to preemptive therapy. Adenovirus
viremia was seen in 3 patients (7%). Invasive fungal infec-
tions were diagnosed in 3 patients (7%), including 2 patients
with a fatal outcome, both of whom had the infection before
transplantation.
After FCC HSCT, 9 patients (20%) developed autoimmune-
like pathologies, including 4 patients with hemolytic anemia,
4 patients with pure red cell aplasia (1 of whom also had
immune thrombocytopenia and 1 who had thyroiditis), and
1 patient with probable immune-mediated neutropenia
that responded to granulocyte colony-stimulating factor
(Supplementary Table S1). All 4 patients with pathology
classiﬁed as warm-type autoimmune hemolytic anemia
responded to prednisolone, but 3 of these patients re-
lapsed. Two of these 3 patients responded to rituximab
therapy; the other patient, who received a 9/10 HLA-matched
HSCT, had refractory and fulminant hemolysis in associa-
tion with severe GVHD and multiple thromboses. Among the
4 patients with pure red cell aplasia (PRCA), 3 received amajor
ABO mismatched transplant that was the likely cause of the
PRCA. Three of these 4 patients recovered, attaining trans-
fusion independence, whereas in 1 patient the PRCA was
refractory to steroids, i.v. immunoglobulin, rituximab, and
donor lymphocyte infusion. This patient underwent a second
HSCT from an alternative ABO-matched unrelated donor.
Lymphocyte reconstitution after FCC HSCT
Serial analysis of peripheral blood lymphocytes of 29 FCC
HSCT recipients showed the expected lymphopenia associ-
ated with the use of alemtuzumab, with the total number of
lymphocytes remaining signiﬁcantly below normal (P < .0001)
at 1 year and beyond (Figure 1B). Natural killer (NK) cells were
the predominant lymphocyte population present early post-
HSCT, representing 49.3% of lymphocytes at day +30 (Figure 1C).
B cells were not detected at day 30 but rapidly recovered, rep-
resenting 31.7% of lymphocytes at day 60 (Figure 1C), and
remained signiﬁcantly above normal at day 360 (23.7%, com-
pared with 10.5% for healthy volunteers; P = .002%).
T cell deﬁciency is prolonged, and the CD8 T cell
population is skewed to an effector phenotype
T cells were profoundly deﬁcient, representing only 11.3%
of lymphocytes at day 30, and increasing to 43.8% at 1 year,
but still signiﬁcantly below normal (67.2%; P = .018)
(Figure 1C). Rapid recovery of B cells with prolonged T cell
deﬁciency produced abnormal dominance of B cells over T
cells, which was maintained in the long term. The percent-
age of CD4 T cells in the T cell population was lower than
normal, producing inversion of the usual CD4:CD8 T cell ratio
(Figure 1D). Memory and effector T cells predominated early
post-HSCT (Figure 1E). Naïve T cells began to recover after 6
months (Figure 1E). The proportions of naïve, memory, and
effector subsets within the CD4 T cell population were near
normal at 1 year (Figure 1E, left). In contrast, CD8 T cell subset
composition remained abnormal at 1 year owing to a high
proportion of effector T cells (57.2%, compared with 9.3% for
healthy volunteers; P < .0001) (Figure 1E, right).
Persistence of recipient CD8 T cells after FCC HSCT
Lymphocyte subsets from 5 patients with mixed T cell chi-
merism at 1 year were isolated by ﬂuorescence-activated cell
sorting, and donor/recipient composition was determined by
analysis of informative alleles from polymorphic short tandem
repeat loci. Four patients had >93% donor NK cells and >76%
donor B cells. Patient 3 had only 39% donor NK cells and 76%
donor B cells. Naïve, memory, and effector T cell subsets were
isolated using the gating strategy shown Figure 2A. The results
shown in Figure 2B show that the mixed T cell chimerism at
1 year was due principally to the persistence of recipient CD8
T cells. The median percentage contribution to recipient CD3
chimerism was 37.9% for the CD8 T cell population and 8.5%
for the CD4 T cell population (P = .008). Recipient chime-
rismwas detected in all CD8 T cell subsets, but with a notable
contribution of the effector subset in patients 3 and 4, both
of whom had CMV reactivation early after HSCT. A signiﬁcant
correlation was observed between lower donor T cell chi-
merism at 1 year and CMV reactivation or EBV viremia early
after HSCT. Patients who were donor and/or recipient CMV/
EBV seropositive but had no viremia post-HSCT had a median
of 77% donor CD3 chimerism, compared with 57% donor CD3
chimerism in patients who had viremia post-HSCT (P = .036).
Follow-up analysis of patients 1, 2, and 3 at >2 years post-
HSCT showed that their T cell subset mixed chimerism proﬁle
remained stable after IST cessation, and that the numbers of
CD4 and CD8 T cells did not increase (data not shown).
DISCUSSION
Using the FCC conditioning regimen for allogeneic HSCT
to treat SAA at a single center and with long-term follow up,
we have conﬁrmed the excellent clinical outcomes re-
ported in our previous multicenter study [5]. The incidence
Table 2
Patient Outcomes After FCC HSCT
Outcome Value
Time to neutrophil count >0.5 × 109/L, d, median
(range)
12 (10-22)
Time to platelet count >20 × 109/L, d, median (range) 12 (9-61)
Primary graft failure, n (%) 1 (2.2)
Acute GVHD, n (%) 6 (13.3)
Grade I/II 6
Grade III/IV 0
Chronic GVHD, n (%) 6 (13.3)
Mild 4
Moderate 1
Severe 1
1-year TRM, n (%) 3 (6.6)
5-year OS, % 93.1
5-year EFS, % 90.7
5-year EFS, MSD (n = 12) versus UD (n = 33), % 100 versus 87.4
(P = .219)
5-year EFS, age ≤50 yr (n = 31) versus >50 yr
(n = 14), %
93 versus 85.7
(P = .356)
FCC indicates ﬂudarabine, cyclophosphamide, and alemtuzumab (Campath-
1H); HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-
host disease; TRM, transplantation-related mortality; OS, overall survival;
EFS, event-free survival; MSD, matched sibing donor; UD, unrelated
donor.
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of chronic GVHD was remarkably low, particularly given the
high proportion of matched unrelated donors in this cohort.
The comparable outcome of older (age >50 years) and younger
patients is also encouraging, given that increasing age is typ-
ically associated with worse outcomes [13]. Rapid full donor
myeloid engraftment occurred, and there was only 1 case of
graft failure, associated with a low infused bonemarrow stem
cell dose. The majority of patients exhibited sustained mixed
T cell chimerism that persisted despite withdrawal of im-
munosuppression at 1 year after transplantation.
The alemtuzumab-containing FCC regimen caused pro-
found and prolonged T cell depletion, particularly in CD4 T
cells, which recoveredmore slowly than CD8 T cells. The small
numbers of T cells that survived depletion with alemtuzumab
were almost exclusively of the memory or effector subsets
and dominated the circulating population for at least 6
months. We previously reported the same selective preser-
vation of antigen-experienced T cells after HSCT using a
ﬂudarabine, busulfan, and alemtuzumab regimen for treat-
ment of patients with hematologicmalignancies [14]. The very
Figure 1. Serial analysis of peripheral blood chimerism and lymphocyte composition after FCC HSCT. (A) Percentage donor chimerism of unfractionated, pu-
riﬁed CD3 and puriﬁed CD15 peripheral blood cells. Mean and SEM are shown. (B) Reconstitution of peripheral blood lymphocytes after FCC HSCT. Median
and interquartile range are shown, and the horizontal dotted lines enclosing gray boxes represent the median and interquartile range of 11 adult healthy
volunteers. Comparisons between cell numbers at each time point and healthy volunteers were performed using a 2-tailed Mann-Whitney U test. Lympho-
cyte numbers at all time points were signiﬁcantly below numbers for healthy volunteers (P < .0005). (C) Percentage of NK, B, and T cells. Mean and SEM are
shown, and values for 11 adult healthy volunteers (HV) are indicated. (D) Percentage of CD4 and CD8 T cells within the CD3 T cell population using mean
values. (E) Percentages of naïve, memory, and effector subset composition of CD4 T cells (left) and CD8 T cells (right). Mean and SEM are shown, and values
for 11 adult healthy volunteers (HV) are indicated.
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slow recovery of T cells is likely due to thymic atrophy in
adults, which limited de novo production of naïve T cells after
HSCT. The combination of Tcell depletion and the relatively
mild conditioning with ﬂudarabine and low-dose cyclophos-
phamide, which is unlikely to induce a strong cytokine storm,
limits the potential for T cell alloreactivity. Of the 7 pa-
tients who developed GVHD, 6 had >90% donor CD3
chimerism and 1 had 75% donor CD3 chimerism by day 60.
Mixed T cell chimerism is frequent after reduced-intensity
conditioning and particularly common after TCD with
alemtuzumab [15]. Our investigation of mixed chimerism
within T cell subsets found that CD4 T cells were mainly
donor-derived by 1 year but that CD8 T cells remained pre-
dominantly recipient-derived. Although naïve, memory, and
effector subset frequencies in the CD4 T cell population were
near normal by 1 year, numbers were low in all patients, and
deﬁciencies persisted after cessation of IST. In contrast,
recovery of CD8 T cells was much more robust, but an atyp-
ical composition developed owing to expansion of the effector
CD8 T cell subset, which rose from a mean of 17.6% CD8 T
cells at day +90 to 57.2% at 1 year (compared with 9.3% for
healthy volunteers). Recipient cells were present in all CD8
T cell subsets but was notably high in the effector popula-
tion, particularly for the 2 patients who experienced CMV
reactivation early after HSCT.
Expansion of the effector CD8 T cell population occurred
despite continued IST for at least 1 year. CMV reactivation and
EBV viremia early after transplantation were correlated with
higher recipient CD3 chimerism at 1 year; thus, we specu-
late that the expansion of effector CD8 T cell numbers may
be due to antigen-driven proliferation of pathogen-speciﬁc
recipient CD8 T cells. Limited sample availability and low T
cell numbers precluded our investigation of the antigen speci-
ﬁcity of the effector CD8 T cells. The incidence of viral disease
Figure 2. Analysis of individual patients showed sustained mixed T cell chimerism at 1 year after FCC HSCT is due primarily to persistence of recipient CD8
T cells, with notable contribution of the effector subset. (A) Panels illustrate the gating strategy used for isolation of naïve, memory, and effector T cell subsets
by FACS. (B) CD4 T cell (left) and CD8 T cell (right) subset chimerism at 1 year for 5 patients. CMV serostatus of donor/recipient and reactivation early post
HSCT: patient 1, negative/negative; patient 2, negative/positive no reactivation; patient 3, positive/negative and reactivation; patient 4, negative/positive and
reactivation; patient 5, negative/positive no reactivation.
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post-FCC was low, despite EBV and CMV viremia in 47% and
42% of patients, respectively. Recipient-derived effector CD8
T cells may confer a degree of antivirus immunity after FCC
HSCT, despite continued IST. Other recent studies have re-
ported that virus-speciﬁc CD8 T cells can have a substantial
impact on T cell composition after HSCT. Massive expan-
sion of CMV-speciﬁc effector CD8 T cells is seen following CMV
reactivation after HSCT and has a long-term impact on
T cell reconstitution [16,17]. In the setting of TCD using
alemtuzumab-based reduced-intensity conditioning in pa-
tients undergoing transplantation for hematologic
malignancies, Sellar et al. showed that CMV-speciﬁc CD8 T
cells were of recipient origin and contributed signiﬁcantly to
higher recipient chimerism [18].
For patients with hematologic malignancies, routine clin-
ical practice is to administer donor lymphocyte infusion (DLI)
formixed T cell chimerism to promote conversion to full donor
chimerism and prevent disease relapse [19]. DLI is not ad-
ministered to patients with SAA after FCC HSCT because
disease relapse does not occur and DLI has the associated risk
of GVHD. Our study of lymphocyte composition and chime-
rism provides novel insight into the long-term impact of HSCT
conditioning with alemtuzumab. Stable coexistence of donor
and recipient T cells for many years after withdrawal of im-
munosuppression, reliable engraftment, and low rates of
GVHD indicates that a state of mutual tolerance exists after
allogeneic FCC HSCT. HLA-matching and T cell depletion using
alemtuzumab together with IST for at least 1 year after HSCT
is an effective strategy to minimize alloreactivity. Although
our study shows that the FCC HSCT regimen results in an atyp-
ical lymphocyte composition, clinical course and outcomes
for patients are remarkably good.
The only complication consistently observed after FCC
HSCT is emergence of autoimmune-like diseases that are pre-
dominantly antibody-mediated cytopenias, seen in 6 patients
(14%) in this study. Secondary autoimmune disorders
commonly occur after treatment with alemtuzumab in other
clinical settings [20]. Prolonged T cell deﬁciency may con-
tribute to dysregulated B cell behavior.We previously reported
that clonal gammopathies are frequent after alemtuzumab-
based HSCT [21]. No association of autoimmune-like disease
with circulating B cells or other lymphocyte populations was
found in our study (data not shown).
In conclusion, despite persistent T cell deﬁciency,
excellent survival and low incidence of viral disease was
observed after FCC HSCT for SAA. The very low incidence
of GVHD with long-term stable mixed T cell chimerism,
shaped by recipient CD8 T cells, in the absence of immuno-
suppression indicates that FCC conditioning favors mutual
tolerance.
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